TNF-alpha blockers represent one of the most important therapeutic strategies for rheumatoid arthritis, but their use has raised the question about their safety profile, particularly in respect to viral infections/reactivations. We describe the case of a patient who developed a symptomatic EBV reactivation 11 days after the first infusion of infliximab.
Epstein-barr virus reactivation after infliximab in rheumatoid arthritis: a case report / Colaci, Michele; Sebastiani, Marco; Sandri, Gilda; Meacci, M; Ferri, Clodoveo. - In: CASE REPORT IN INFECTIOUS DISEASES. - ISSN 2090-6633. - 2011:(2011), pp. 530568-530568.
Epstein-barr virus reactivation after infliximab in rheumatoid arthritis: a case report
SEBASTIANI, Marco;
2011-01-01
Abstract
TNF-alpha blockers represent one of the most important therapeutic strategies for rheumatoid arthritis, but their use has raised the question about their safety profile, particularly in respect to viral infections/reactivations. We describe the case of a patient who developed a symptomatic EBV reactivation 11 days after the first infusion of infliximab.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
